Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
2641-2660 of 3,900 trials

Avacopan for Children with Active ANCA-associated Vasculitis

We are studying how well Avacopan works when combined with other treatments in children aged 6 to under 18 with active ANCA-associated vasculitis. The trial will also look at safety and how children respond to the medication.

ANCA-associated Vasculitis1-2 yearsConfirmation phase (III)11-15 visitsNo PlaceboInvestigational MedicinesCost ReimbursementInternal MedicineRheumatology

Osteosarcoma: Mifamurtide with Chemotherapy

We are studying whether adding mifamurtide to standard chemotherapy helps improve outcomes for patients with high-risk osteosarcoma. This trial is for individuals aged 2 to 50 who are newly diagnosed with this aggressive cancer.

High-Risk Osteosarcoma6-12 monthsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Gastroenteropancreatic Neuroendocrine Tumors: New Liver Treatment

We are studying a new way to deliver radiolabeled treatments directly to the liver for patients with GEP-NET and dominant liver metastases. This trial aims to see if this method improves treatment effectiveness and safety.

Gastroenteropancreatic Neuroendocrine Tumors>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementGastroenterologyInternal MedicineOncology

Prostate Cancer: Enzalutamide Study

We are investigating how Enzalutamide affects molecular changes in men with localized prostate cancer before and after surgery. This study may help us understand its impact on cell growth and gene activity.

Prostate Cancer>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesOncologyUrology

Relapsed or Refractory Tumors: AcSé-ESMART Trial

We are studying new treatment options for children and adolescents with hard-to-treat tumors. The goal is to see if these treatments are safe and effective based on the specific characteristics of their tumors.

Pediatric Cancer>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesOncologyPediatrics

Kidney Transplant: Optimal Dose of Grafalon®

We are studying the best dose of Grafalon® for kidney transplant patients with low immunological risk. This trial aims to prevent complications and evaluate the medication's safety and effects on kidney function and infections.

Kidney TransplantKidney Insufficiency>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesInternal MedicineNephrology

Post-Surgery Pain Management: Ropivacaine Concentration Study

We are investigating whether different concentrations of ropivacaine can help reduce pain after volar plate surgery. This study aims to see if higher doses lead to less rebound pain and better overall pain control.

Radius Fracture>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesPartially RemoteOrthopedics and TraumatologyOtolaryngologyPsychiatry

Thyroid Eye Disease: TOUR006 Treatment Study

We are investigating whether the new treatment TOUR006 can reduce eye bulging in adults with thyroid eye disease. Participants will receive either the treatment or a placebo to compare effects.

Thyroid Eye Disease1-2 yearsEfficacy phase (II)≤5 visitsInvestigational MedicinesCost ReimbursementEndocrinologyOphthalmology

Kidney Health After Liver Transplant: Human Albumin Study

We are investigating whether higher doses of human albumin can help reduce kidney problems after liver transplantation. This study looks at various recovery aspects, including hospital stay and potential complications.

Liver Transplantation≤3 monthsMonitoring phase (IV)No PlaceboStandard MedicinesHepatologyNephrology

Lung Cancer: Pembrolizumab and Lenvatinib Combination Therapy

We are studying a new combination treatment for patients with operable Non-Small-Cell Lung Cancer to see if it improves response rates before surgery. We also aim to identify markers that may predict how well patients respond to this therapy.

Non-Small-Cell Lung Cancer1-2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesOncologyPulmonology

Ovarian Cancer: Rinatabart Sesutecan (Rina-S) Study

We are comparing a new treatment, Rina-S, to standard therapies for patients with platinum-resistant ovarian cancer. The goal is to see if Rina-S can help improve survival without disease progression.

Platinum-resistant Ovarian Cancer>2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesOncology

Chronic Lymphocytic Leukemia: Ibrutinib and Obinutuzumab Treatment

We are studying a combination of ibrutinib and obinutuzumab for newly diagnosed patients with Chronic Lymphocytic Leukemia. The aim is to see if this treatment effectively reduces cancer cells in the bone marrow.

Chronic Lymphocytic Leukemia (CLL)>2 yearsEfficacy phase (II)>20 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesOncology

Advanced Solid Tumors: OSE-279 Treatment Study

We are investigating a new monoclonal antibody, OSE-279, for patients with advanced solid tumors or lymphomas. The study aims to find the best dose and evaluate its safety and effectiveness compared to existing treatments.

Stage IV Non-Small Cell Lung CancerAdvanced Solid TumorsLymphoma1-2 yearsSafety phase (I)Efficacy phase (II)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOncology

Rectal Cancer: Ferumoxtran-10 MRI Study

We are testing a new MRI method to see if it better identifies lymph node involvement in patients with newly diagnosed rectal cancer. This may help doctors plan more effective treatments.

Rectal CancerMesorectal Lymph Node Metastases>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesOncologyOtolaryngology

Urinary Incontinence: Mesenchymal Stem Cells Study

We are exploring the use of mesenchymal stem cells for women over 50 with urinary incontinence. This study aims to determine if this treatment is safe and feasible for this age group.

Urinary Incontinence in Older WomenSafety phase (I)Gynecology and ObstetricsUrology

Vitamin D for Low Testosterone in Men with Type 2 Diabetes

We are studying whether vitamin D supplements can help increase testosterone levels in men with type 2 diabetes. This trial compares the effects of vitamin D to a placebo.

Type 2 Diabetes≤3 monthsEfficacy phase (II)≤5 visitsPost-Trial Drug AccessStandard MedicinesEndocrinologyInternal Medicine

Severe Asthma: Predicting Response to Benralizumab

We are studying whether early blood tests can predict how well severe asthma patients respond to Benralizumab treatment. This may help identify those who are likely to experience fewer asthma attacks.

Severe Asthma>2 yearsMonitoring phase (IV)≤5 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteAllergologyPulmonology

Unilateral Retinoblastoma: Adjuvant Treatment Study

We are studying additional treatments for patients with unilateral retinoblastoma after eye removal. The goal is to understand how these treatments affect recovery and any potential side effects.

Retinoblastoma>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncologyOphthalmology

Ensifentrine for Non-Cystic Fibrosis Bronchiectasis

We are studying whether nebulized ensifentrine can help reduce lung flare-ups in people with non-cystic fibrosis bronchiectasis. The trial also examines its impact on respiratory symptoms and overall quality of life.

Non-Cystic Fibrosis Bronchiectasis>2 yearsEfficacy phase (II)≤5 visitsInvestigational MedicinesPulmonology

CRN04894 for Hormonal Imbalance

We are studying the safety and effectiveness of CRN04894 in participants with hormonal imbalances. The goal is to see how it affects hormone levels and overall health.

Congenital Adrenal HyperplasiaEfficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteEndocrinologyPediatrics